Prognostic and Predictive Biomarkers in Nonmetastatic Colorectal Cancers

References

• Gustavsson B , CarlssonG, MachoverDet al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorect. Cancer14(1), 1–10 (2015).
   PubMed Web of Science ®Google Scholar
• Rodrigues D , Longatto-FilhoA, MartinsSF. Predictive biomarkers in colorectal cancer: from the single therapeutic target to a plethora of options. BioMed Res. Int.2016 (2016).
   Web of Science ®Google Scholar
• Fariña-Sarasqueta A , van LijnschotenG, MoerlandEet al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol.21(12), 2396–2402 (2010).
   PubMed Web of Science ®Google Scholar
• Lièvre A , BachetJ-B, BoigeVet al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Ohrling K , EdlerD, HallströmM, RagnhammarP. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Acta Oncol. Stockh. Swed.49(6), 797–804 (2010).
   PubMed Web of Science ®Google Scholar
• Shen Y , HanX, WangJet al. Prognostic impact of mutation profiling in patients with stage II and III colon cancer. Sci. Rep.6, 24310–24317 (2016).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA . DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat. Rev. Clin. Oncol.7(3), 174–177 (2010).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , MarsoniS, MongesGet al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol.28(20), 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• He EY , HawkinsNJ, MakGet al. The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: an Australian population-based multicenter study. Oncologist21(5), 618–625 (2016).
   PubMed Web of Science ®Google Scholar
• Zaanan A , Cuilliere-DartiguesP, GuillouxAet al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease- free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol.21(4), 772–780 (2010).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM , NiedzwieckiD, ComptonCCet al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol.27(11), 1814–1821 (2009).
   PubMed Web of Science ®Google Scholar
• Klingbiel D , SaridakiZ, RothAD, BosmanFT, DelorenziM, TejparS. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann. Oncol.26(1), 126–132 (2015).
   PubMed Web of Science ®Google Scholar
• Boland PM , MaWW. Immunotherapy for colorectal cancer. Cancers9(5), 50–62 (2017).
   PubMed Web of Science ®Google Scholar
• Kim ST , KlempnerSJ, ParkSHet al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget8(44), 77415–77423 (2017).
   PubMedGoogle Scholar
• Broderick JM . FDA approves pembrolizumab for microsatellite instability-high and mismatch repair deficient cancers. OncLive23rd May (2017).
   Google Scholar
• Roth AD , TejparS, DelorenziMet al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J. Clin. Oncol.28(3), 466–474 (2010).
   PubMed Web of Science ®Google Scholar
• Taieb J , ZaananA, Le MalicotKet al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol.14, 1–11 (2016).
   Google Scholar
• Jones JC , GrotheyA. Understanding BRAF-mutant colorectal cancer. ASCO Daily News26th May (2016). https://am.asco.org/daily-news/understanding-braf-mutant-colorectal-cancer.
   Google Scholar
• Phipps AI , BuchananDD, MakarKWet al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br. J. Cancer108(8), 1757–1764 (2013).
   PubMed Web of Science ®Google Scholar
• Hu J , YanW-Y, XieLet al. Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore)95(50), (2016).
   Web of Science ®Google Scholar
• Blons H , EmileJF, Le MalicotKet al. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 Phase III trial dataset. Ann. Oncol.25(12), 2378–2385 (2014).
   PubMed Web of Science ®Google Scholar
• Kim HS , HeoJS, LeeJet al. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. BMC Cancer16, 120 (2016).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , BalogounR, CayreAet al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann. Oncol.27(Suppl. 6), 459 (2016).
   Google Scholar
• Sartore-Bianchi A , TrusolinoL, MartinoCet al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, Phase 2 trial. Lancet Oncol.17(6), 738–746 (2016).
   PubMed Web of Science ®Google Scholar
• Fontanges Q , De MendoncaR, SalmonI, Le MercierM, D’HaeneN. Clinical application of targeted next generation sequencing for colorectal cancers. Int. J. Mol. Sci.17(12), 2117–2127 (2016).
   PubMed Web of Science ®Google Scholar
• Domingo E , Freeman-MillsL, RaynerEet al. Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol. Hepatol.1, 207–216 (2016).
   PubMed Web of Science ®Google Scholar
• Eng C . POLE mutations in colorectal cancer: a new biomarker?Lancet Gastroenterol. Hepatol.1(3), 176–177 (2016).
   PubMed Web of Science ®Google Scholar
• Ahn S-M , AnsariAA, KimJet al. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget7(42), 68638–68649 (2016).
   PubMedGoogle Scholar
• Nebot-Bral L , BrandaoD, VerlingueLet al. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur. J. Cancer84, 290–303 (2017).
   PubMed Web of Science ®Google Scholar
• Dalerba P , SahooD, PaikSet al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N. Engl. J. Med.374(3), 211–222 (2016).
   PubMed Web of Science ®Google Scholar
• Pilati C , TaiebJ, BalogounR, MarisaL, de ReynièsA, Laurent-PuigP. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Ann. Oncol.28(5), 1032–1035 (2017).
   PubMed Web of Science ®Google Scholar
• Guinney J , DienstmannR, WangXet al. The consensus molecular subtypes of colorectal cancer. Nat. Med.21(11), 1350–1356 (2015).
   PubMed Web of Science ®Google Scholar
• Tie J , WangY, TomasettiCet al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med.8(346), 346ra92 (2016).
   PubMed Web of Science ®Google Scholar
• Danielsen SA , EidePW, NesbakkenA, GurenT, LeitheE, LotheRA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim. Biophys. Acta1855(1), 104–121 (2015).
   PubMed Web of Science ®Google Scholar
• Rosty C , YoungJP, WalshMDet al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS ONE8(6), e65479 (2013).
   PubMed Web of Science ®Google Scholar
• Fariña Sarasqueta A , ZeestratenECM, van WezelTet al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell. Oncol. Dordr.34(6), 523–531 (2011).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Liao X , MorikawaT, LochheadPet al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res.18(8), 2257–2268 (2012).
   PubMed Web of Science ®Google Scholar
• Domingo E , ChurchDN, SieberOet al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol.31(34), 4297–4305 (2013).
   PubMed Web of Science ®Google Scholar
• Liao X , LochheadP, NishiharaRet al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med.367(17), 1596–1606 (2012).
   PubMed Web of Science ®Google Scholar
• Paleari L , PuntoniM, ClavarezzaM, DeCensiM, CuzickJ, DeCensiA. PIK3 CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin. Oncol. (R. Coll. Radiol.)28(5), 317–326 (2016).
   PubMed Web of Science ®Google Scholar